Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.37)
# 334
Out of 5,154 analysts
118
Total ratings
52.29%
Success rate
18.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $44.83 | +29.38% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $253.69 | +11.95% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $61.12 | +40.71% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $29.86 | +50.70% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $5.69 | +23.13% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $12.58 | +58.98% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $21.25 | +144.71% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.11 | +92.93% | 4 | Dec 12, 2025 | |
| PHVS Pharvaris | Maintains: Buy | $32 → $39 | $25.91 | +50.52% | 1 | Dec 4, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $28 → $43 | $25.95 | +65.70% | 8 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $16.71 | +13.70% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $6.85 | +337.96% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $14.27 | +565.73% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $74.04 | +24.26% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $39.68 | +167.14% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $8.40 | +19.05% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.44 | +4.17% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $456.69 | +19.56% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $14.86 | +236.47% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $26.54 | +107.23% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.01 | +348.88% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.34 | +49.91% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.34 | +4.60% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $56.50 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.61 | +312.15% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.90 | +464.10% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.30 | +1,160.87% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $320.66 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $4.57 | +512.69% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $13.12 | +52.44% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $32.92 | +273.63% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $24.08 | +124.25% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.13 | +5,209.73% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.47 | - | 3 | Jun 26, 2017 |
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $44.83
Upside: +29.38%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $253.69
Upside: +11.95%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $61.12
Upside: +40.71%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $29.86
Upside: +50.70%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $5.69
Upside: +23.13%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $12.58
Upside: +58.98%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $21.25
Upside: +144.71%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.11
Upside: +92.93%
Pharvaris
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $25.91
Upside: +50.52%
Centessa Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $28 → $43
Current: $25.95
Upside: +65.70%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $16.71
Upside: +13.70%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $6.85
Upside: +337.96%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $14.27
Upside: +565.73%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $74.04
Upside: +24.26%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $39.68
Upside: +167.14%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $8.40
Upside: +19.05%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.44
Upside: +4.17%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $456.69
Upside: +19.56%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $14.86
Upside: +236.47%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $26.54
Upside: +107.23%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $4.01
Upside: +348.88%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.34
Upside: +49.91%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.34
Upside: +4.60%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $56.50
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.61
Upside: +312.15%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.90
Upside: +464.10%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.30
Upside: +1,160.87%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $320.66
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $4.57
Upside: +512.69%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $13.12
Upside: +52.44%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $32.92
Upside: +273.63%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $24.08
Upside: +124.25%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.13
Upside: +5,209.73%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $27.47
Upside: -